Secure future manufacturing for advanced therapies

Cell and gene therapy

One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell, or gene therapies that require pDNA as a starting material. 

Watch this free webinar – Early phase support for plasmid DNA supply helps secure future manufacturing for advanced therapies – for an in-depth discussion of the challenges CGT innovators face and how experts resolve these barriers through adopting technologies and strategies that drive an optimised plasmid production process and supply.

The webinar, hosted by DDW and supported by Catalent, was presented by Matthias Craig, Senior Manager Product Development, Catalent.

Watch now.

You will learn:

  • Key considerations during plasmid production including design and screening systems, processing, and analytical testing.
  • Discover how to reduce batch-to-batch inconsistencies, improve plasmid purity, and enhance plasmid yield at every stage of upstream and downstream operations.
  • The advantages of securing plasmid bioproduction services that are fully integrated within viral vector and cell therapy manufacturing capabilities.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free